- Conditions
- Thyroid Associated Ophthalmopathies, Thyroid-Associated Ophthalmopathy
- Interventions
- teprotumumab, normal saline
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 82
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Graves Disease
- Interventions
- BHV-1300, Placebo
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 40
- States / cities
- Tucson, Arizona • Burbank, California • Huntington Beach, California + 34 more
- Conditions
- Ocular Motility Disorders, Strabismus, Extraocular Muscle Dysfunction, Thyroid Eye Disease
- Interventions
- Glandy EOM (AI-based quantitative eye movement analysis software)
- Device
- Lead sponsor
- THYROSCOPE INC.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Jose, California
- Conditions
- Thyroid Cancer, Graves Disease
- Interventions
- Cervical Collar Therapy Indicator (COTI)
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Thyroid Eye Disease
- Interventions
- Veligrotug
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Inglewood, California • Los Angeles, California • Palo Alto, California + 20 more
- Conditions
- Graves Disease
- Interventions
- WP1302, WP1302 placebo, methimazole
- Drug · Combination Product
- Lead sponsor
- Worg Biotherapeutics Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 7
- States / cities
- Hunt, Arizona • Canoga Park, California • Littleton, Colorado + 4 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Teprotumumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 3
- States / cities
- Miami, Florida • St Louis, Missouri • Bellaire, Texas
- Conditions
- Thyroid Eye Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Mission Hills, California • Rancho Cordova, California + 8 more
- Conditions
- Thyroid Eye Disease
- Interventions
- Efgartigimod PH20 SC, Placebo PH20 SC
- Combination Product · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more
- Conditions
- Thyroid Eye Disease, TED, Graves Orbitopathy
- Interventions
- linsitinib, Placebo
- Drug
- Lead sponsor
- Sling Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Graves' Disease
- Interventions
- Levothyroxine, Placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Graves' Disease
- Interventions
- Felzartamab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Asheville, North Carolina • Dallas, Texas
- Conditions
- Graves' Dysthyroid Ophthalmopathy, Thyroid Related Orbitopathy
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Silkiss, Rona Z., M.D., FACS
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Oakland, California • New York, New York
- Conditions
- Thyroid Eye Disease
- Interventions
- lonigutamab, Placebo
- Drug
- Lead sponsor
- ACELYRIN Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Ann Arbor, Michigan + 3 more
- Conditions
- Graves' Disease
- Interventions
- Experimental: YB-101, Placebo YB-101
- Drug
- Lead sponsor
- Yarrow Bioscience, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 26
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • La Mesa, California + 23 more
- Conditions
- Thyroid Eye Disease
- Interventions
- VRDN-003, Placebo
- Drug
- Lead sponsor
- Viridian Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 37
- States / cities
- Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 27 more
- Conditions
- Graves Disease
- Interventions
- MER511 (IV), Placebo comparator (IV), MER511 (SC), Placebo comparator (SC), MER511 (SC) for MAD, Placebo comparator (SC) for MAD
- Biological
- Lead sponsor
- Merida Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Torrance, California • Hollywood, Florida • Miami, Florida + 8 more
- Conditions
- Graves Disease, Hashimoto Disease
- Interventions
- Dexamethasone, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana
- Conditions
- Thyroid Eye Disease, Graves' Orbitopathy
- Interventions
- Teprotumumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Miami, Florida • Skokie, Illinois + 5 more
- Conditions
- Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
- Interventions
- SNP analysis
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Thyroid Eye Disease
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hashimoto's Disease, Graves' Disease
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 7 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Thyroid Eye Disease
- Interventions
- Hyaluronic Acid Gel injection, Saline injection
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2021
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy, Thyroid Associated Ophthalmopathy, Endocrine System Diseases, Orbital Diseases, Proptosis, Eye Diseases
- Interventions
- LASN01, Placebo
- Drug
- Lead sponsor
- Lassen Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Beverly Hills, California • Palo Alto, California • San Diego, California + 6 more